+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 3 Actively Recruiting clinical trials

D

Actively Recruiting

Researchers are studying the daily use of Rifapentine combined with Isoniazid to prevent tuberculosis in children under 13 years old, including those with and without HIV. This Phase III trial aims to find the appropriate dose of this combination taken once daily for 28 days. The study will include up to 144 children divided into two groups based on HIV status and will take place at multiple locations. Participants will receive the study drugs by oral dispersible tablets, grouped by weight into five categories. Children with HIV will also be assessed for their use of Dolutegravir as part of their antiretroviral therapy. The treatment period lasts 28 days, followed by a 24-week follow-up to monitor safety, tolerability, and drug levels in the blood. Both groups will be closely observed to assess how the drugs are processed in their bodies and any adverse effects. During the study, participants will have blood tests to measure drug concentrations and monitor liver, kidney, and blood cell function. Parent or guardian reports on treatment acceptability and adherence will be collected. Researchers will track adverse events throughout the treatment and follow-up periods. The total participation duration includes the initial 28-day dosing phase and subsequent 24 weeks of monitoring to ensure safety and effectiveness of the regimen.

Age: 0 - 13YearsAll GendersPhase 1Phase 2
11 locations
C

Actively Recruiting

Researchers are evaluating the safety and effectiveness of a new short 6-week daily rifapentine treatment compared to the standard 12-16 week rifamycin-based treatments for latent Mycobacterium tuberculosis infection LTBI. This trial focuses on people at higher risk of developing active tuberculosis TB and is conducted in locations with varying TB rates where LTBI treatment is routinely provided. The study aims to determine if the shorter treatment is not less safe or effective than the longer standard treatments. Participants are randomly assigned to one of two treatment groups the experimental group receives 600 mg of rifapentine daily for 6 weeks, while the control group receives one of three standard regimens lasting 12 to 16 weeks, including combinations of rifapentine, isoniazid, and rifampin. Dose adjustments are made based on patient weight following established guidelines. Treatments are given according to random assignment and participants are followed for 24 months to assess outcomes. During the study, researchers monitor treatment completion rates, adverse drug reactions, and new cases of active tuberculosis. Safety assessments include tracking serious side effects and drug discontinuation rates. Effectiveness is measured by the occurrence of culture-confirmed or clinical TB within 24 months of enrollment. The study involves regular evaluations and follow-up visits over two years to collect data on treatment tolerability, safety, and TB prevention outcomes.

All AgesAll GendersPhase 2Phase 3
21 locations
E

Actively Recruiting

Researchers are studying the effects of early intensive antiretroviral therapy ART with or without broadly neutralizing antibodies on achieving HIV remission in infants living with HIV. This phase III study includes two groups infants born to mothers with limited or no antiretroviral use during pregnancy and infants diagnosed with HIV within 48 hours of birth who start ART immediately. The goal is to see if early treatment can suppress HIV to undetectable levels. Participants will receive one of seven intensive ART regimens combining nucleoside reverse transcriptase inhibitors NRTIs with drugs like nevirapine, lopinavirritonavir, raltegravir, dolutegravir, and monoclonal antibodies VRC01 or VRC07-523LS. Therapy begins within 48 hours of birth and may include switches in medication based on age and weight. The study has four steps initial evaluation and therapy start, up to 192 weeks of treatment with monitoring, possible treatment interruption for those with sustained viral suppression, and re-initiation of ART if viral rebound occurs. During the study, infants undergo regular HIV testing, safety monitoring, and immune assessments. Researchers track how many achieve HIV remission by week 48 and monitor viral suppression and adverse events through week 192. If treatment interruption is attempted, participants are closely observed for viral rebound for up to ten years, followed by monitoring after ART re-initiation until age five or six months after viral suppression. The entire study may last several years to evaluate long-term outcomes.

Age: 0 - 48HoursAll GendersPhase 1Phase 2
47 locations